A General Public Study on Preferences and Welfare Impacts of Antimicrobial Resistance in the United Kingdom

Maria Veronica Dorgali, Alberto Longo, Caroline Vass, Gemma Shields, Roger Harrison, Riccardo Scarpa and Marco Boeri
Additional contact information
Maria Veronica Dorgali: Queen’s University Belfast
Alberto Longo: Queen’s University Belfast
Caroline Vass: RTI Health Solutions, RTI International
Gemma Shields: The University of Manchester
Roger Harrison: The University of Manchester

PharmacoEconomics, 2022, vol. 40, issue 1, No 7, 65-76

Abstract: Abstract Background Antibiotics have led to considerable increases in life expectancy. However, over time, antimicrobial resistance has accelerated and is now a significant global public health concern. Understanding societal preferences for the use of antibiotics as well as eliciting the willingness to pay for future research is crucial. Objective To investigate preferences for different strategies to optimize antibiotic use and to understand the willingness to pay for future research in antimicrobial resistance and antimicrobial drug development. Methods A discrete-choice experiment was administered to a sample of the UK general population. Respondents were asked to make nine choices, each offering three options—two hypothetical “doctor and antibiotics” and one “no doctor—no antibiotics”—defined by five attributes: treatment, days needed to recover, risk of bacterial infection that needs antibiotics, risk of common side effects, and risk of antimicrobial resistance by 2050. Data were analyzed using random parameters logit models. A double-bounded contingent valuation was also included in the survey to explore the willingness to pay for policies to contain antimicrobial resistance. Results Among the 2579 respondents who completed the survey, 1151 always selected “no doctor—no antibiotics” and 57 never varied their choices; therefore, 1371 responses were used in the analysis. Risk of antimicrobial resistance by 2050 was the most important attribute and the “treatment” was the least important attribute, although this was sensitive to a higher risk of bacterial infection. The aggregate annual willingness to pay for containing antimicrobial resistance was approximately £8.35 billion (~£5–£10 billion). Conclusions The antimicrobial resistance risk is relevant and important to the general public. The high willingness to pay suggests that large investments in policies or interventions to combat antimicrobial resistance are justified.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01076-9 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:40:y:2022:i:1:d:10.1007_s40273-021-01076-9

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01076-9

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().